Brief: Bridge Biotherapeutics Launches A Research Collaboration With Emory University School Of Medicine
28/03/2024 22:04
March 28 (Reuters) - Bridge Biotherapeutics Inc
288330.KQ :
* BRIDGE BIOTHERAPEUTICS LAUNCHES A RESEARCH COLLABORATION
WITH
EMORY UNIVERSITY SCHOOL OF MEDICINE TO EXPLORE COMBINATION
THERAPY OF BBT-877 FOR KRAS/P53 MUTANT NSCLC PATIENTS RESISTANT
TO ANTI-PD-1 BLOCKADE
Source text for Eikon: ID:nPn4h5clWa
Further company coverage: 288330.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Parataxis Korea
See all newsBrief: Parataxis, Bridge Biotherapeutics Ink Deal to List Bitcoin Treasury Firm on Korea's KOSDAQ
Brief: Bridge Biotherapeutics Announces Completion Of Enrollment In The Phase 2A Clinical Study Of BBT-877 For The Treatment Of Idiopathic Pulmonary Fibrosis
Brief: Bridge Biotherapeutics Launches A Research Collaboration With Emory University School Of Medicine
Brief: Bridge Biotherapeutics Announces A Research Collaboration With The University Of Colorado School Of Medicine
Brief: Bridge Biotherapeutics To Conduct Capital Increase Of 2 Billion Won For Operational Funds